Maurizio Scaltriti
0000-0002-5522-1447
Publication & Citation Trends
Most Cited Works
Publications
663 total
Abstract 3999: Combination of T-DXd with the irreversible pan-HER TKI afatinib drives combination benefit in HER2-low gastric and lung tumors
Cited by 0
Semantic Scholar
Abstract PS18-13: Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models
Cited by 0
Semantic Scholar
High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer OA
Cited by 14
Semantic Scholar
Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing OA
Cited by 1
Semantic Scholar
José Baselga 1959–2021 OA
Cited by 0
Semantic Scholar
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins OA
Cited by 25
Semantic Scholar
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer OA
Cited by 34
Semantic Scholar
The present and future of PI3K inhibitors for cancer therapy OA
Cited by 157
Semantic Scholar
Research Topics
PI3K/AKT/mTOR signaling in cancer
(172)
HER2/EGFR in Cancer Research
(155)
Lung Cancer Treatments and Mutations
(137)
Advanced Breast Cancer Therapies
(112)
Monoclonal and Polyclonal Antibodies Research
(77)
Frequent Co-Authors
Affiliations
Université Claude Bernard Lyon 1
AstraZeneca (United Kingdom)
Institució Catalana de Recerca i Estudis Avançats
University of Modena and Reggio Emilia
Hebron University